De Rubertis Francesco's Form 4 filing
Centessa Pharmaceuticals plc (CNTA) · filed Nov 30, 2021
- Accession no.
- 0000899243-21-046320
- Filed
- Nov 30, 2021
- Trade date
- Nov 26-29, 2021
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 4 non-derivative transactions. Open-market purchases total $797.5K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| De Rubertis FrancescoCIK 0001601521 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 26, 2021 | Ordinary Shares | PPurchaseAcquired | +11,543 | $11.34 | +$130,897.62 | 3,753,152 | Indirect | |
| Nov 26, 2021 | Ordinary Shares | PPurchaseAcquired | +274 | $11.34 | +$3,107.16 | 89,161 | Indirect | |
| Nov 29, 2021 | Ordinary Shares | PPurchaseAcquired | +55,391 | $11.70 | +$648,074.7 | 3,808,543 | Indirect | |
| Nov 29, 2021 | Ordinary Shares | PPurchaseAcquired | +1,315 | $11.70 | +$15,385.5 | 90,476 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.